A Phase I, Randomized, Placebo-controlled, Ascending Single And Multiple Oral Dose Study To Investigate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Hetrombopag Olamine (SHR8735 Olamine) In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Apr 2015
Price : $35 *
At a glance
- Drugs Hetrombopag (Primary)
- Indications Thrombocytopenia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 03 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Apr 2014 New trial record